{"id":"NCT03954626","sponsor":"Novartis Pharmaceuticals","briefTitle":"Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD","officialTitle":"A Single-Arm, Open-Label, Multicenter, Phase IIIb Study to Collect Safety and Electrocardiogram Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-07","primaryCompletion":"2019-07-09","completion":"2019-07-31","firstPosted":"2019-05-17","resultsPosted":"2020-08-13","lastUpdate":"2021-01-05"},"enrollment":14,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Age-Related Macular Degeneration","Macular Degeneration","Wet Macular Degeneration","Retinal Degeneration","Retinal Diseases","Eye Diseases"],"interventions":[{"type":"BIOLOGICAL","name":"brolucuzumab 6 mg IVT","otherNames":["RTH258"]}],"arms":[{"label":"RTH258","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to collect ECG data after a single IVT injection of brolucizumab 6 mg in patients with neovascular age-related macular degeneration (nAMD).","primaryOutcome":{"measure":"Frequency of Clinically Relevant Treatment Emergent ECG Changes After Intravitreal Injection of Brolucizumab 6 mg in Patients With nAMD","timeFrame":"Baseline, Hour 20, Hour 22, Hour 24","effectByArm":[{"arm":"RTH258","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":19},"locations":{"siteCount":3,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["35301822"],"seeAlso":["https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=383"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Intraocular pressure increased"]}}